InnoCyte GmbH Finds Further Investors
26-Nov-2012
- Germany
InnoCyte GmbH has developed a technology that standardizes, automates, accelerates and therefore significantly simplifies and reduces the cost of producing biological cells. The cell production as such is a key process in biological and medical research, for example in the development of medication („pharma screening“) or when creating artificial tissue („tissue engineering“).
Most read news
Organizations
Innocyte
High-Tech Gründerfonds Management
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.